Catabasis Pharmaceuticals Earlier Reported Q3 EPS $(0.56) Beats $(0.64) Estimate

Catabasis Pharmaceuticals (NASDAQ:CATB) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.64) by 12.5 percent. This is a 600 percent decrease over losses of $(0.08) per share

Benzinga · 11/07/2019 14:45

Catabasis Pharmaceuticals (NASDAQ:CATB) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.64) by 12.5 percent. This is a 600 percent decrease over losses of $(0.08) per share from the same period last year.